IsoRay Receives FDA 510(k) Clearance for GammaTileTM Therapy

On July 9, IsoRay, Inc. (ISR) and GT Medical Technologies, Inc. announced they received FDA 510(k) regulatory clearance for their brachytherapy technology, known as GammaTile^TMTherapy. The therapy incorporates proprietary Cesium-131 seeds within customizable collagen-based carriers to treat recurrent brain tumors. The two companies previously executed a ten-year collaborative development agreement.

 

Sonal detected the event at 1:51 pm and issued an alert. The next trade took place at 2:02 pm for $0.75.  The stock price immediate spiked over twice the opening price before fading back over the next hour. The stock price, however, pushed higher for the remainder of the trading day to close at $1.14 for a gain of almost 87%.

If you want to learn more about trading on clinical trial results, visit the Knowledge Center.

To see the latest weekly webinar, you can visit our Live Webinar page.

Subscribe here if you would like to start receiving these signals in real-time and start trading!